Revolution Medicines

Revolution Medicines recorded $198 million in sales within just over a month after US approval of Rasonque (Daraxonrasib) and dispensed the drug to more than 5,000 patients. Revenues far exceeded estimates in the high double‑digit millions. The CHMP of the EMA issued a positive opinion in October; final EU approval from the European Commission is still pending. The company is building regional commercial leadership teams in Europe, Canada and Japan, and the stock jumped sharply following the quarterly results. » More on deraktionaer.de

The CHMP of the EMA has issued a positive opinion for Rasonque (Daraxonrasib) to treat adults with metastatic pancreatic adenocarcinoma after prior therapy. The decision now goes to the European Commission, which is expected to follow the opinion; the FDA had already approved the drug at the end of August. Studies showed that Rasonque roughly doubled participants’ survival time compared with chemotherapy. Price and reimbursement questions remain at the member-state level, and Revolution Medicines’ stock fell about six percent after the news. » More on deraktionaer.de

Parnassus Growth Equity Fund added Revolution Medicines as a new holding, citing strong late-stage clinical data for daraxonrasib in pancreatic cancer that could establish a new standard of care and drive significant commercial opportunity. The fund highlighted Revolution Medicines' broader potential across other cancers and its fit within long-term health care innovation themes. Recent company developments include FDA approval of Rasonque for metastatic pancreatic cancer, underscoring near-term commercialization prospects. » More on finance.yahoo.com

Revolution Medicines’ stock rose to an all-time high of $220.8 and is currently trading at $223.96, well above its 52-week low. The price jump followed the FDA approval of RASONQUE (Daraxonrasib) for metastatic ductal pancreatic adenocarcinoma and prompted target adjustments from several brokerages. H.C. Wainwright, Oppenheimer, Guggenheim and others raised price targets, while some analysts warned that a risk‑adjusted valuation may already be priced in. Revolution Medicines also launched two Phase 3 trials for non-small cell lung cancer, highlighting progress in its product pipeline. » More on de.investing.com

The FDA has approved Daraxonrasib, now marketed as Rasonque, for the treatment of metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or for patients who are not candidates for multi-agent systemic therapy. The approval followed an accelerated review under the CNPV program; the application was submitted in July. The monthly wholesale list price for the once-daily tablet is reported as $39,800, not accounting for possible discounts of 20–30 percent. Revolution Medicines also has two other drug candidates in its portfolio, while high market valuations are already priced into the stock. » More on deraktionaer.de